LDTs have become increasingly important in clinical practice but put patients at risk and increase healthcare costs when they are inaccurate or are not supported by scientific evidence

CSPI supports the efforts by the FDA to regulate LDTs, as a modern regulatory framework will improve patient access to reliable tests.

View resource